Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Radius Health Inc (RDUS) Up On Positive Trial Data: Should You Buy?

Pharmaceutical company Radius Health Inc (NASDAQ:RDUS), which concentrates on developing products designed to treat osteoporosis, saw its shares rise by more than 15% yesterday following the release of positive clinical data related to its investigational drug abaloparatide. According to Radius Health Inc (NASDAQ:RDUS), these trials show that the drug has met the primary and secondary endpoints, which are necessary to help it prepare the drug for regulatory submission. While Radius is making its effort to enter a big market, investors should keep in mind that Radius is still a high-risk company which is currently burning more than $60 million in operating cash per year as it works to develop abaloparatide.



At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 142% and beating the market by more than 84 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.

In today’s marketplace there are plenty of gauges shareholders can use to assess publicly traded companies. A couple of the lesser known gauges are hedge fund and insider trading activity. Experts at Insider Monkey, a website specializing in hedge funds,  has shown that historically, those who follow the top picks of the top money managers can outclass their index-focused peers by a very impressive margin. Let’s look first at the recent insider trading activity, which we see was relatively neutral. There were no recorded insider sales, and the only insider purchases were made by a large institutional shareholder, not a company executive, so we don’t consider those insider purchases to be as strong an indicator.

Let’s take a look at the latest hedge fund activities on Radius Health Inc (NASDAQ:RDUS) now.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.